4.8 Article

Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant

期刊

JOURNAL OF PHYSICAL CHEMISTRY LETTERS
卷 13, 期 17, 页码 3840-3849

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jpclett.2c00469

关键词

-

资金

  1. NIH [GM126189]
  2. NSF [DMS-2052983, DMS-1761320, IIS-1900473]
  3. NASA [80NSSC21M0023]
  4. Michigan Economic Development Corporation
  5. MSU Foundation
  6. Pfizer
  7. Bristol-Myers Squibb [65109]

向作者/读者索取更多资源

The BA.2 subvariant of the Omicron variant shows increased infectivity and vaccine escape capability, making it likely to become the next dominant variant and posing a serious threat to existing monoclonal antibodies.
The Omicron variant has three subvariants: BA.1 (B.1.1.529.1), BA.2 (B.1.1.529.2), and BA.3 (B.1.1.529.3). BA.2 is found to be able to alarmingly reinfect patients originally infected by Omicron BA.1. An important question is whether BA.2 or BA.3 will become a new dominating variant of concern. Currently, no experimental data has been reported about BA.2 and BA.3. We construct a novel algebraic topology-based deep learning model to systematically evaluate BA.2's and BA.3's infectivity, vaccine breakthrough capability, and antibody resistance. Our comparative analysis of all main variants, namely, Alpha, Beta, Gamma, Delta, Lambda, Mu, BA.1, BA.2, and BA.3, unveils that BA.2 is about 1.5 and 4.2 times as contagious as BA.1 and Delta, respectively. It is also 30% and 17-fold more capable than BA.1 and Delta, respectively, to escape current vaccines. Therefore, we project that Omicron BA.2 is on a path to becoming the next dominant variant. We forecast that like Omicron BA.1, BA.2 will also seriously compromise most existing monoclonal antibodies. All key predictions have been nearly perfectly confirmed before the official publication of this work.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据